NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Gainers Stablecoin Development (AMEX:SDEV) shares moved upwards by 66.9% to $6.11 during Friday&#39

Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to

Guggenheim analyst Michael Schmidt maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lo

Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with AT

Analysts downgraded FHTX, BUSE, ASTS, ATRC and EQBK; targets fell for BUSE, ASTS and EQBK but rose f

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Foghorn Therapeutics (NASDAQ:FHTX)

U.S. stocks edged higher Thursday; Nasdaq rose 0.37%, energy led gains, Accenture surged 18%, and Co

Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's re

Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of

Foghorn Therapeutics stock drops as Eli Lilly ends partnership, prompting a 40% workforce cut to ext

U.S. stocks slipped Thursday as the Dow fell over 200 points; energy and oil rose, Micron beat estim

Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-m

Foghorn Therapeutics and Eli Lilly don't plan any future collaborations following the dissolution of

Following a review of clinical data from the Phase 1 dose escalation trial of FHD-909 (LY4050784), F

Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SM

The consensus price target hints at a 67% upside potential for Foghorn Therapeutics (FHTX). While em

Does Foghorn Therapeutics Inc. (FHTX) have what it takes to be a top stock pick for momentum investo

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to an 88.5% upside in the

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.1 per share versus the Zacks C

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.10) per share which beat the ana

- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung ca

Sunshine Biopharma (NASDAQ: SBFM - Get Free Report) and Foghorn Therapeutics (NASDAQ: FHTX - Get Fre

Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being highe

Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contribute

Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a cli

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clin

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.29 per share versus the Zacks

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the anal

- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti

Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a l

- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4

Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new cl

Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform a

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX)

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pion

BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy

Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a

Guggenheim analyst Michael Schmidt initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.25) per share which beat the ana

- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B deg

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.28) per share which beat the ana

JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Marke

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.30) per share which beat the ana